Advance in research of hepatorenal syndrome
-
摘要: <正>肝肾综合征(Hepatorenal syndrome,HRS)是肝功能障碍终末期的严重并发症,以肾脏血管显著收缩为特征,最终导致肾脏血流灌注和肾小球滤过率明显下降,肾脏的水钠排泄功能受损。尽管HRS是一种可逆性、功能性肾功能损伤,但一旦发生,预后极差,存活率很低。目前临床上血管活性药物、白蛋白的应用可以改善肾功能,提高患者生存率,但最终有效治疗方案仍是肝移植[1]。随着对其发病机制、
-
关键词:
- 肝肾综合征
-
Key words:
- hepatorenal syndrome
-
[1]Fasolato S, Angeli P, Dallagnese L, et al.:Renal failure and bac-terial infections in patients with cirrhosis:epidemiology and clinicalfeatures[J].Hepatology, 2007, 45 (1) ∶223-229. [2]Helvig FC, Schutz CB. A liver and kidney syndrome: clinical, pathological, and experimental studies[J]. Surg Gynecol Obstet, 1932, 55 (4) ∶570-582. [3]Gines P, Guevara M, Arroyo V, et al. Hepato-renal syndrome[J]. Lancet, 2003, 362 (9398) ∶1819-1827. [4]Vicente Arroyo, Carlos Terra, Pere Gine`s.Advances in the patho-genesis and treatment of type-1 and type-2 hepatorenalsyndrome[J].Journal of Hepatology, 2007, 46 (5) ∶935-946. [5]Terra C, Guevara M, Torre A, et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score[J]. Gastroenterology, 2005, 129 (6) ∶1944-1953. [6]Fasolato S, Angeli P, Dallagnese, L, et al.Renal failure and bac-terial infections in patients with cirrhosis:epidemiology and clinicalfeatures[J].Hepatology, 2007, 45 (1) ∶223-229. [7]Fernandez J, Monteagudo J, Bargallo X, et al.A randomized un-blinded pilot study comparing albumin versus hydroxyethyl starch inspontaneous bacterial peritonitis[J].Hepatology, 2005, 42 (43) ∶627-634. [8]Moore K, Wong F, Gines P, et al.The management of ascites incirrhosis:report on the consensus conference of the international as-cites club[J].Hepatology, 2003, 38 (1) ∶258-266. [9]Gines A, Escorsell A, Gines P, et al.Incidence, predictive factorsand prognosis of the hepato-renal syndrome in cirrhosis with asci-tes[J].Gastroenterology, 1993, 105 (1) ∶229-236. [10]Hennenberg M, Trebicka J, Sauerbruch T, et al. Mechanisms of extrahepatic vasodilation in portal Hypertension[J].Gut, 2008, 57 (9) ∶1300-1314. [11]Sieber CC, Lopeztalavera JC, Groszmann RJ. Role of nitric-oxide in the invitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats[J]. Gastroenterology, 1993, 104 (6) ∶1750-1754. [12]Coll M, GenescàJ, Raurell I, et al.Genetic down-regulation ofgenes related to the adrenergic system might have a role in splanch-nic vasodilation of portal hypertension[J].Journal of Hepatology, 2008, 49 (1) ∶43-51. [13]Geerts AM, De Vriese AS, Vanheule E, et al.Increased angiogen-esis and permeability in the mesenteric microvasculature of rats withcirrhosis and portal hypertension:an in vivo study[J].Liver Int, 2006, 26 (7) ∶889-898. [14]Ruiz-del-Arbol W, Urman J, Fernandez J, et al.Systemic, re-nal, and hepatic hemodynamic derangement in cirrhotic patientswith spontaneous bacterial peritonitis[J].Hepatology, 2003, 38 (5) ∶1210-1218. [15]Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrom cirrhosis[J]. Hepatology, 2005, 42 (2) ∶439-447. [16]Ma ZH, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter[J]. Hepatology, 1996, 24 (2) ∶451-459. [17]Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis[J]. Journal of Hepatology, 2008, 48 (suppl 1) ∶ S93-S103. [18]Arroyo V, Colmenero J.Ascites and hepatorenal syndrome in cir-rhosis:pathophysiological basis of therapy and currentmanagement[J].J Hepatol, 2003, 38 (suppl 1) ∶S69-S89. [19]Wadei HM, Mai ML, Ahsan N, et al.Hepatorenalsyndrome:Patho-physiology and management[J].Clin J AmSoeNePhrol, 2006, 1 (5) ∶1066-1079. [20]Stadlbauer V, Wright GAK, Banaji M, et al. Relationship between activation of the sympathetic nervous system and renal blood flow auto regulation in cirrhosis[J]. Gastroenterology, 2008, 134 (1) ∶111-119. [21]Papadakis MA, Arieff AI. Unpredictability of clinical-evaluation of renal-function in cirrhosis prospective-study[J]. Am J Med, 1987, 82 (5) ∶945-952. [22]Caregaro L, Menon F, Angeli P, Amodio P, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis[J]. Arch Intern Med, 1994, 154 (2) ∶201-205. [23]Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls[J]. Am J Kidney Dis, 2003, 41 (2) ∶269-278. [24]Gtzberger M., Kaiser C, Landauer N, et al.Intrarenal resistanceindex for the assessment of early renal function impairment in pa-tients with liver cirrhosis[J].European Journal of Medical Re-search, 2008, 13 (8) ∶383-387.
本文二维码
计量
- 文章访问数: 2024
- HTML全文浏览量: 13
- PDF下载量: 694
- 被引次数: 0